Crossmark Global Holdings Inc. Trims Holdings in Hill-Rom Holdings, Inc. (HRC)

Share on StockTwits

Crossmark Global Holdings Inc. reduced its stake in Hill-Rom Holdings, Inc. (NYSE:HRC) by 34.8% during the fourth quarter, Holdings Channel reports. The fund owned 6,765 shares of the medical technology company’s stock after selling 3,610 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Hill-Rom were worth $599,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Advisors Asset Management Inc. boosted its stake in shares of Hill-Rom by 41.4% during the 4th quarter. Advisors Asset Management Inc. now owns 18,499 shares of the medical technology company’s stock worth $1,638,000 after purchasing an additional 5,417 shares during the period. Xact Kapitalforvaltning AB boosted its stake in shares of Hill-Rom by 5.4% during the 4th quarter. Xact Kapitalforvaltning AB now owns 9,802 shares of the medical technology company’s stock worth $868,000 after purchasing an additional 500 shares during the period. Crescent Grove Advisors LLC purchased a new position in shares of Hill-Rom during the 4th quarter worth about $2,286,000. Nkcfo LLC purchased a new position in shares of Hill-Rom during the 4th quarter worth about $162,000. Finally, Arizona State Retirement System boosted its position in Hill-Rom by 2.4% in the 4th quarter. Arizona State Retirement System now owns 48,292 shares of the medical technology company’s stock valued at $4,276,000 after buying an additional 1,141 shares during the period. Institutional investors own 86.96% of the company’s stock.

In other news, SVP Andreas G. Frank sold 7,454 shares of the business’s stock in a transaction dated Wednesday, November 28th. The shares were sold at an average price of $95.76, for a total value of $713,795.04. Following the completion of the sale, the senior vice president now owns 27,224 shares in the company, valued at approximately $2,606,970.24. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.73% of the stock is owned by insiders.

Hill-Rom stock opened at $103.50 on Thursday. The stock has a market capitalization of $6.84 billion, a price-to-earnings ratio of 21.79, a P/E/G ratio of 1.45 and a beta of 0.95. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.70 and a quick ratio of 1.25. Hill-Rom Holdings, Inc. has a 1 year low of $79.36 and a 1 year high of $105.78.

Hill-Rom (NYSE:HRC) last released its quarterly earnings data on Friday, January 25th. The medical technology company reported $1.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.98 by $0.04. The company had revenue of $683.50 million during the quarter, compared to analysts’ expectations of $676.39 million. Hill-Rom had a net margin of 7.21% and a return on equity of 21.23%. The firm’s quarterly revenue was up 2.1% on a year-over-year basis. During the same period in the previous year, the company earned $0.92 EPS. As a group, research analysts expect that Hill-Rom Holdings, Inc. will post 5.06 earnings per share for the current fiscal year.

HRC has been the subject of several research reports. Zacks Investment Research reissued a “buy” rating and issued a $106.00 price objective on shares of Hill-Rom in a research report on Tuesday, November 13th. ValuEngine raised shares of Hill-Rom from a “hold” rating to a “buy” rating in a research report on Tuesday, November 6th. UBS Group initiated coverage on shares of Hill-Rom in a research report on Tuesday, November 27th. They issued a “buy” rating and a $115.00 price objective for the company. Finally, Morgan Stanley lowered their price objective on shares of Hill-Rom from $100.00 to $98.00 and set an “equal weight” rating for the company in a research report on Wednesday, January 2nd. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $102.67.

COPYRIGHT VIOLATION WARNING: “Crossmark Global Holdings Inc. Trims Holdings in Hill-Rom Holdings, Inc. (HRC)” was originally reported by Week Herald and is owned by of Week Herald. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://weekherald.com/2019/02/14/crossmark-global-holdings-inc-trims-holdings-in-hill-rom-holdings-inc-hrc.html.

About Hill-Rom

Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.

Featured Article: Bear Market

Want to see what other hedge funds are holding HRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hill-Rom Holdings, Inc. (NYSE:HRC).

Institutional Ownership by Quarter for Hill-Rom (NYSE:HRC)

Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply